Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
暂无分享,去创建一个
M. Pfisterer | F. Van de Werf | J. Tijssen | M. Simoons | D. de Bono | A. Arnold | A. Betriu | C. Burgersdijk | L. López Bescós | E. Mueller | D. D. de Bono
[1] A. Tonkin,et al. A Randomized Comparison of Intravenous Heparin With Oral Aspirin and Dipyridamole 24 Hours After Recombinant Tissue‐Type Plasminogen Activator for Acute Myocardial Infarction , 1991, Circulation.
[2] D. Tate,et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.
[3] J. Hsia,et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.
[4] G. Porro,et al. Cyclosporin treatment for severe active ulcerative colitis , 1990, The Lancet.
[5] R. Collins,et al. GISSI-2: 10% reduction in mortality with heparin in acute myocardial infarction? , 1990, The Lancet.
[6] White Hd. GISSI-2 and the heparin controversy. , 1990 .
[7] H. White. GISSI-2 and the heparin controversy , 1990, The Lancet.
[8] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.
[9] T. A. S. Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin , 1990, The Lancet.
[10] R. Zelis,et al. Recent Insights Into the Calcium Channels , 1989, Circulation.
[11] F. Feit,et al. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial. , 1989, Circulation.
[12] K. Lee,et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.
[13] Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.
[14] F. Van de Werf,et al. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.
[15] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[16] Dwight E. Peake,et al. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .
[17] R. W. Brower,et al. [Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]. , 1988, Klinische Wochenschrift.
[18] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[19] E. Topol,et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. , 1987, Journal of the American College of Cardiology.
[20] Harold T. Dodge,et al. Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .
[21] R. W. Brower,et al. DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION , 1985, The Lancet.
[22] Gary Halvorson,et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Verstraete M, Bory M, Erbel R, et al Lancet 842–847 Apr 13, 1985 , 1985 .
[23] R. W. Brower,et al. RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.
[24] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[25] A. Van der Laarse,et al. Assessment of myocardial damage in patients with acute myocardial infarction by serial measurement of serum alpha-hydroxybutyrate dehydrogenase levels. , 1984, American heart journal.